Clinical Trial Update: Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial update outlines safety, tolerability, pharmacokinetics and the recommended Phase 2 dose for livmoniplimab alone and in combination with budig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Solid Tumors

Drugs mentioned

• Budigalimab (ABBV-181) (budigalimab)
• Livmoniplimab (ABBV-151) (livmoniplimab)

Snippet

Sponsor: AbbVie | Conditions: Advanced Solid Tumors Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING